Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation

被引:231
作者
Asai, O
Longo, DL
Tian, ZG
Hornung, RL
Taub, DD
Ruscetti, FW
Murphy, WJ
机构
[1] NCI, Intramural Res Support Program, SAIC Frederick, Frederick Canc Res & Dev Ctr, Ft Detrick, MD 21702 USA
[2] NCI, Lab Leukocyte Biol, SAIC Frederick, Frederick Canc Res & Dev Ctr, Ft Detrick, MD 21702 USA
[3] NIA, Gerontol Res Ctr, Baltimore, MD 21224 USA
关键词
NK cell; graft-versus-host disease; bone marrow transplantation; immunotherapy; cytokines;
D O I
10.1172/JCI1268
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Bone marrow transplantation (BMT) is currently used for the treatment of a variety of neoplastic diseases. However, significant obstacles limiting the efficacy of allogeneic BMT are the occurrence of graft-versus-host disease (GvHD) and tumor relapse. Natural killer (NK) cells exert a variety of immunologic and homoeostatic functions. We examined whether adoptive transfer of activated NK cells of donor type would prevent GvHD after allogeneic BMT in mice. Lethally irradiated C57BL/6 (H-2(b)) mice, were transplanted with MHC incompatible BALB/c (H-2(d)) bone marrow cells and spleen cells and rapidly succumbed to acute GvHD. In contrast, mice that also received activated NK cells of donor type exhibited significant increases in survival. In determining the mechanism by which the NK cells prevented GvHD, mice were concurrently treated with a neutralizing antibodies to the immunosuppressive cytokine TGF beta. Anti-TGF beta completely abrogated the protective effects of the activated donor NK cells indicating that TGF beta plays an important role in the prevention of GvHD by NK cells. We then examined whether activated NK cells of donor type after allogeneic BMT would induce graft-versus-tumor (GvT) effects without GvHD in mice bearing a murine colon adenocarcinoma (MCA-38). 10 d after receiving the tumor, in which the mice had demonstrable lung metastases, recipients received an allogeneic BMT with or without activated NK cells. Administration of activated NK cells resulted in significant GvT effects after allogeneic BMT as evidenced by increases in median survival and fewer lung metastasis. No evidence of GVHD was detected compared with recipients receiving spleen cells alone which also developed fewer lung metastases but in which all had succumbed to GVHD. Thus, our findings suggest that adoptive immunotherapy using activated donor NK cells combined with allogeneic BMT inhibits GvHD and promotes GvT in advanced tumor-bearing mice. These results also suggest that GvT and GvHD can be dissociable phenomena.
引用
收藏
页码:1835 / 1842
页数:8
相关论文
共 24 条
[1]   BONE-MARROW TRANSPLANTATION [J].
ARMITAGE, JO .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (12) :827-838
[2]   INCREASING UTILIZATION OF ALLOGENEIC BONE-MARROW TRANSPLANTATION - RESULTS OF THE 1988-1990 SURVEY [J].
BORTIN, MM ;
HOROWITZ, MM ;
RIMM, AA .
ANNALS OF INTERNAL MEDICINE, 1992, 116 (06) :505-512
[3]  
DASCH JR, 1989, J IMMUNOL, V142, P1536
[4]  
FAVROT MC, 1989, BONE MARROW TRANSPL, V4, P499
[5]  
FERRARA JLM, 1991, NEW ENGL J MED, V324, P667
[6]   PREVENTION OF MURINE GRAFT-VERSUS-HOST DISEASE BY INDUCING AND ELIMINATING ASGM1+ CELLS OF DONOR ORIGIN [J].
GHAYUR, T ;
SEEMAYER, TA ;
LAPP, WS .
TRANSPLANTATION, 1988, 45 (03) :586-590
[7]   Graft-versus-leukaemia activity can be predicted by natural cytotoxicity against leukaemia [J].
Glass, B ;
Uharek, L ;
Zeis, M ;
Loeffler, H ;
MuellerRuchholtz, W ;
Gassmann, W .
BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 (02) :412-420
[8]   BONE-MARROW TRANSPLANTATION FOR CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE - INCREASED RISK FOR RELAPSE ASSOCIATED WITH T-CELL DEPLETION [J].
GOLDMAN, JM ;
GALE, RP ;
HOROWITZ, MM ;
BIGGS, JC ;
CHAMPLIN, RE ;
GLUCKMAN, E ;
HOFFMANN, RG ;
JACOBSEN, SJ ;
MARMONT, AM ;
MCGLAVE, PB ;
MESSNER, HA ;
RIMM, AA ;
ROZMAN, C ;
SPECK, B ;
TURA, S ;
WEINER, RS ;
BORTIN, MM .
ANNALS OF INTERNAL MEDICINE, 1988, 108 (06) :806-814
[9]  
HABU S, 1981, J IMMUNOL, V127, P34
[10]   PRODUCTION OF GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTOR BY HUMAN NATURAL-KILLER-CELLS - MODULATION BY THE P75 SUBUNIT OF THE INTERLEUKIN-2 RECEPTOR AND BY THE CD2 RECEPTOR [J].
LEVITT, LJ ;
NAGLER, A ;
LEE, F ;
ABRAMS, J ;
SHATSKY, M ;
THOMPSON, D .
JOURNAL OF CLINICAL INVESTIGATION, 1991, 88 (01) :67-75